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Abstract
Nipah virus (NiV) and Hendra virus (HeV) are zoonotic paramyxoviruses capable of causing severe disease in
humans and animals. These viruses require biosafety level 4 (BSL-4) containment. Like other
paramyxoviruses, the plaque reduction neutralization test (PRNT) can be used to detect antibodies to the
surface glycoproteins, fusion (F) and attachment (G), and PRNT titers give an indication of protective
immunity. Unfortunately, for NiV and HeV, the PRNT must be performed in BSL-4 containment and takes
several days to complete. Thus, we have developed a neutralization assay using VSV pseudotype particles
expressing the F and G proteins of NiV (pVSV-NiV-F/G) as target antigens. This rapid assay, which can be
performed at BSL-2, was evaluated using serum samples from outbreak investigations and more than 300
serum samples from an experimental NiV vaccination study in swine. The results of the neutralization assays
with pVSV-NiV-F/G as antigen showed a good correlation with those of standard PRNT. Therefore, this new
method has the potential to be a rapid and cost-effective diagnostic method, especially in locations that lack
high containment facilities, and will provide a valuable tool for basic research and vaccine development.
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a b s t r a c t
Nipah virus (NiV) and Hendra virus (HeV) are zoonotic paramyxoviruses capable of causing severe dis-
ease in humans and animals. These viruses require biosafety level 4 (BSL-4) containment. Like other
paramyxoviruses, the plaque reduction neutralization test (PRNT) can be used to detect antibodies to
the surface glycoproteins, fusion (F) and attachment (G), and PRNT titers give an indication of protective
immunity. Unfortunately, for NiV and HeV, the PRNTmust be performed in BSL-4 containment and takes
several days to complete. Thus, we have developed a neutralization assay using VSV pseudotype particles
expressing the F and G proteins of NiV (pVSV-NiV-F/G) as target antigens. This rapid assay, which can be
performed at BSL-2, was evaluated using serum samples from outbreak investigations andmore than 300
serum samples from an experimental NiV vaccination study in swine. The results of the neutralization
assays with pVSV-NiV-F/G as antigen showed a good correlation with those of standard PRNT. Therefore,
this new method has the potential to be a rapid and cost-effective diagnostic method, especially in loca-
tions that lack high containment facilities, and will provide a valuable tool for basic research and vaccine
development.
Published by Elsevier B.V.
1. Introduction
Nipah virus (NiV) and Hendra virus (HeV) are recently emer-
gent, related paramyxoviruses that can cause severe diseases in
humans and animals. These viruses are the only two members of a
newlynamedgenus,Henipavirus,within the familyParamyxoviridae
(Bellini et al., 2005;Wang et al., 2001). HeV emerged in Australia in
1994 and caused severe respiratory disease in humans and horses
(Murrayet al., 1995). Therehavebeen sporadic casesofHeV through
2006 (Anon., 2008; Field et al., 2007; Westbury, 2000a,b), but the
virus has not been detected outside of Australia. The ﬁrst out-
break of NiV occurred in 1998–1999 inMalaysia and Singapore, and
was manifested as a respiratory disease in swine and fatal, febrile
encephalitis in humans (Chua et al., 2000). In 2001, NiV outbreaks
occurred in Siliguri, India (Chadha et al., 2006; Harit et al., 2006).
 The ﬁndings and conclusions in this report are those of the authors and do not
necessarily represent the views of the Centers for Disease Control and Prevention.
∗ Corresponding author. Tel.: +1 404 639 4181; fax: +1 4 4639 4187.
E-mail address: prota@cdc.gov (P.A. Rota).
From 2001 to 2004, four outbreaks of NiV took place in Bangladesh
involving 93 patients with a 73% case fatality rate (Hossain et al.,
2008). In theMalaysianoutbreak, pigs served as the amplifyinghost
and transmitted the virus to humans (Chew et al., 2000; Chua et
al., 2000; Lam and Chua, 2002; Paton et al., 1999). Unlike Malaysia
(Mounts et al., 2001), person-to-person transmission and food-
borne infection of NiV was reported in Bangladesh (Gurley et al.,
2007a,b; Luby et al., 2006). Nucleotide sequencing studies showed
that NiV strains in India were more closely related to those in
Bangladesh than Malaysia (AbuBakar et al., 2004; Harcourt et al.,
2004). Fruit bats were found to be the main reservoir of both HeV
andNiV (Chuaet al., 2002;Halpin et al., 2000). Five species of bats in
peninsular Malaysia had antibodies to NiV (Yob et al., 2001). More
recently, antibodies toNipah-like virusesweredetectedamongbats
in Bangladesh (Hsu et al., 2004), Cambodia (Olson et al., 2002;
Reynes et al., 2005), Thailand (Wacharapluesadee et al., 2005),
Madagascar (Lehle et al., 2007), India (Epstein et al., 2008), China
(Li et al., 2008) and Ghana (Hayman et al., 2008). The widespread
distribution of fruit bats suggests that spillover of NiV from this
reservoir into the human population could occur in many coun-
tries within Southeast Asia and sub-Saharan Africa with serious
0166-0934/$ – see front matter. Published by Elsevier B.V.
doi:10.1016/j.jviromet.2009.02.025
2 A. Tamin et al. / Journal of Virological Methods 160 (2009) 1–6
consequences for both human health and agriculture (Epstein et
al., 2006; Hayman et al., 2008).
Enzyme-linked immunoassay (ELISA) and RT-PCR were used
as a ﬁrst-line diagnostic test in suspected NiV outbreaks (Daniels
et al., 2001). However, since there is an approximately 2% false
positive rate in the ELISA, conﬁrmatory testing was performed
by using a serum neutralizing antibody test (Daniels et al.,
2001). The neutralization test requires live NiV and must be
performed at biosafety level 4 (BSL-4) creating a signiﬁcant chal-
lenge for countries lacking high containment facilities. Therefore,
there is a need to develop alternative diagnostic methods for
detecting antibodies to NiV that can be performed at BSL-2 con-
ditions.
Like other paramyxoviruses, neutralizing antibodies to NiV
are targeted to the fusion (F) and the attachment (G) glycopro-
teins (Bossart et al., 2002; Tamin et al., 2002). This manuscript
reports on the development of a novel assay to detect neutraliz-
ing antibodies to NiV. The target antigen is a vesicular stomatitis
virus (VSV) pseudotype particle (pVSV) displaying NiV-F and -
G (pVSV-NiV-F/G) and expressing a luciferase reporter gene. The
inhibition of entry of the pseudotype particle by antibodies to
the surface glycoproteins of NiV can be detected by measuring
the level of luciferase activity following infection of Vero cells.
Because no infectious NiV is used, this assay can be performed
at BSL-2 and completed within 48h. The results compared favor-
ably to those of a standard plaque reduction neutralization test
(PRNT).
2. Materials and methods
2.1. Cells and viruses
Vero cells were maintained in Dulbecco’s Modiﬁed Essen-
tial Medium (DMEM) containing 10% fetal calf serum (FCS),
l-glutamine, penicillin, and streptomycin (GIBCO BRL). The produc-
tionof pVSV-NiV-F/Gwasdescribedpreviously (Aguilar et al., 2007;
Negrete et al., 2005, 2006). The experimental NiV vaccine based on
recombinant canarypox (CP) expressing either the F (CP-F), or G
(CP-G) proteins of NiV was described previously (Weingartl et al.,
2006).
2.2. Experimental vaccination of pigs with CP-F and CP-G
The details of experimental design, vaccination and sample
collections schedule were described previously (Weingartl et al.,
2006). Brieﬂy, pigs were vaccinated intramuscularly with 108
plaque forming units (pfu) (high dose) or 107 pfu (low dose) of CP-
F, CP-G, or a mixture of both (four animals per group) under BSL-3
conditions. The pigs were boosted 21 days post-vaccination (dpv)
and serum samples were collected from each animal before vacci-
nation (day 0) and at 7, 14, 21, 28, 35 and 49dpv, and the samples
were heat-treated at 56 ◦C for 45min prior to the neutralization
test.
2.3. Enzyme immunoassay with pVSV-NIV-F/G
pVSV-NiV-F/GorpVSVwasdiluted inPBSandadded toduplicate
wells of a ﬂat-bottom 96-well tissue culture plate and incubated
at 37 ◦C for 1h. The plate was washed 5 times with PBS–Tween
buffer (0.1M PBS with 0.05% Tween 20), and primary antibod-
ies from humans or mice diluted 1:200 in blocking buffer (5%
skim milk, 0.1M PBS, 0.05% Tween-20) were added to each well,
and incubated at 37 ◦C for 1h. The plates were washed 5 times
with PBS–Tween buffer, and the corresponding secondary anti-
bodies were added (goat anti-human-HRP, goat anti-mouse-HRP)
and incubated at 37 ◦C for 1h. The plates were washed 5 times
with PBS–Tween buffer, 75l per well of TMB substrate was added
and incubated at room temperature for 15min. The reaction was
stopped by adding 75l per well of 2M phosphoric acid. The
absorbance was then read in an EIA reader at 450nm (TECAN,
Inc.).
2.4. Neutralization test using pVSV-NiV-F/G
The dilution of pseudotype virus usedwas calculated to produce
1500–2000 relative light units (RLUs) in control wells. Fourfold
serial dilutions of the serum samples were prepared in a 96-well
plate beginning with an initial dilution of 1:20 in Minimal Essen-
tial Medium (MEM). An equal volume (55l) of pVSV-NiV-F/G was
added to each well and the plates were incubated at 37 ◦C for
45min. One hundredmicroliters of the pseudotype particle–serum
mixtures were transferred onto 96-well plates containing a mono-
layer of Vero cells. Plates were incubated at 37 ◦C and 5% CO2
for 2h for adsorption after which the innocula were replaced
with 150l of DMEM with 5% fetal bovine serum (FBS) and 1%
penicillin–streptomycin (PS), and the plates were incubated at
37 ◦C and 5% CO2 for 17h. After incubation, the medium was
removed by aspiration, and the plates were washed twice with
200l phosphate-buffered saline (0.01M PBS) per well. Cell lysis
and detection of Renilla Luciferase were performed according to
the protocol recommended by the manufacturer (Promega, Inc.).
Brieﬂy, Renilla Luciferase Assay Lysis Buffer was thawed to room
temperature; diluted 1:5 with ddH20, and 30l was added to
each well. Plates were placed on an orbital shaker for 1–2h with
periodic mechanical manipulation, or by freeze–thawing 3× to
ensure complete lysis of the cells. Following lysis, 25l of the
cell lysates were transferred to a Fluoroskan Ascent FL Fluorom-
eter (Thermo Corporation, Finland) which was pre-programmed
to read for 10 s with a 2 s delay after 100l of Renilla Luciferase
Assay Reagent was added to the well. Percent inhibition was cal-
culated by dividing the average RLU number in triplicate wells
with the test antiserum samples by the average RLU of tripli-
cate wells infected but without antiserum (positive control). A
signal decrease of 90% or greater was considered to be inhi-
bition. The titer of the pVSV-NiV-F/G neutralization assay was
the reciprocal of the highest dilution of serum showing 90% or
higher inhibition. Serum samples that failed to show at least 90%
neutralization at the 1:40 initial dilution were considered nega-
tive.
2.5. Neutralizing assay by plaque reduction neutralization test
(PRNT)
The method for PRNT using live NiV was described previously
(Weingartl et al., 2006), and all procedures with live virus were
performed under BSL-4 conditions. Brieﬂy, PRNT titers were deter-
mined based on a 90% plaque reduction cut-off starting with a 1:20
dilution of serum.
2.6. Radioimmunoprecipitation (RIP) assays
RIP assayswere carried out as described previously (Tamin et al.,
1994) with the single exception that the 35S-methionine-labeled
vv/NiV-F and vv/NiV-G infected cells were resuspended in RIPA
buffer (1% sodiumdeoxycholate, 1% TritonX-100, 0.2% SDS, 150mM
NaCl, and 50mM Tris–HCl at pH 7.5). The human serum samples
usedwere from the recent outbreaks of NiV in Bangladesh (Hossain
et al., 2008). Normal human serum and NiV-speciﬁc hyperimmune
mouse ascites ﬂuid (HMAF)were used as negative and positive con-
trols, respectively. The ratio of antibody to 35S-methionine-labeled
lysate was 1:40.
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Table 1
Antigenic properties of VSV-NiV-FG pseudotype particles.
Antiseruma PRNTb pVSV-NiV-F/Gc
vv/NiV-F + +
vv/NiV-G + +
vv/NiV-N − −
vv/MeV-F − −
NMS − −
pVSV-NiV F/G NDd +
Soluble NiV-G NDd +
NHS − −
+HS + +
CP − −
CP-NiV-F, CP-NiV-G + +
a Serum samples were from mice vaccinated with recombinant vaccinia viruses
expressing NiV-F (vv/NiV-F), NiV-G (vv/NiV-G), NiV-N (vv/NiV-N), measles virus F
(vv/MeV-F) as described previously (Tamin et al., 2002, 1994), normal mouse serum
(NMS), rabbits vaccinatedwith pVSV-NiV-F/G or soluble NiV-G (Negrete et al., 2005,
2006), normal human serum (NHS), serum from a human infected with NiV (+HS),
andpigs vaccinatedwith the canarypox vector alone (CP) or the recombinant viruses
expressing NiV-F and NiV-G (Weingartl et al., 2006).
b PRNT results based on previous publications (Harcourt et al., 2000;Weingartl et
al., 2006).
c Results from the neutralization assay using pVSV-NiV-F/G as antigen described
in this paper.
d ND=not done.
3. Results
3.1. Antigenic properties of pVSV-NiV-F/G
Infection of Vero cells with pVSV-NiV-F/G was inhibited by
monospeciﬁc antiserum to NiV-F and -G, HMAF prepared against
NiV, or a human serum sample from a patient infected with NiV,
all of which also neutralized NiV by standard PRNT (Table 1). Neg-
ative control serum samples included normal human and normal
mouse serumandmonospeciﬁc antiserum to theNiV-Nprotein and
measles virus F protein (Table 1). The results conﬁrmed that pVSV-
NiV-F/G particles had incorporated both the NiV-F and -G proteins
and the infectivity of the particles was neutralized by serum sam-
ples that neutralized NiV in PRNT.
The pseudotype particles were able to serve as NiV-speciﬁc gly-
coprotein antigens in a standard enzyme immunoassay (Fig. 1).
HMAF prepared against NiV (Fig. 1A), serum from mice vacci-
natedwith vaccinia recombinants expressingNiV-F and -G (Fig. 1B),
and a human serum sample from a patient infected with NiV
(Fig. 1B) speciﬁcally recognized pVSV-NiV-F/G bound to the plas-
tic plate. The second antibody-conjugate that was used to detect
the mouse antibody gave higher OD readings than the second anti-
body that was used to detect the human antiserum. There was no
background reactivity when pVSV particles were used as antigen
Fig. 1. Pseudotype particles can serve as antigens in an enzyme immunoassay. Panel
A shows reactivity of HMAF prepared against NiV with pVSV-NiV-F/G and pVSV.
Plates were coated with dilutions of the pseudotype particles as indicated before
being tested by enzyme immunoassay as described in Section 2. Panel B shows
the reactivity of pseudotype pVSV-NiV-F/G with positive (Hu+) and negative (Hu−)
human serum samples and samples from mice vaccinated with recombinant vac-
cinia viruses expressing either NiV-F and -G (anti-rvv/NiV-FG) or measles H and F
(anti-rvv/ChiH-EdF).
(Fig. 1A). Serum samples recognizing the surface glycoproteins of
measles virus and normal human serum did not give a signal in the
enzyme immunoassay format (Fig. 1B). These results indicated that
pVSV-NiV-F/G particles were antigenic and can serve as antigens in
neutralization assays and enzyme immunoassays.
3.2. Antibody responses to NiV infection or experimental
vaccination
Representative serum samples from pigs vaccinated with CP-F,
CP-G or CP-F and CP-G recognized NiV-F and -G in a manner that
was consistent with the vaccination scheme (Fig. 2). However, the
NiV proteins were not detected in the RIP assays until 1 week after
the booster vaccination on day 21 with the exception of the day 21
serum samples from pigs vaccinated with CP-F and CP-G (Fig. 2).
Serum samples from humans infected with NiV recognized both
Fig. 2. Antibody responses following experimental vaccination for NiV. Figure shows results of the RIP assay. Antigens were prepared by infecting Vero cells with vaccinia
viruses expressing NiV-F and -G and labeling with 35S-methionine as described in Section 2. Representative serum samples from pigs that had been vaccinated with
recombinant canarypoxvirus vaccines expressing NiV glycoproteins, CP-F, CP-G, or CP-F and CP-G at 0 (D0), 7 (D7), 14 (D14), 21 (D21), 28 (D28), and 49 (D49) dpv were used.
Lanes C1 and C2 show reactions with mock infected and labeled Vero cells and C3 shows reaction with HMAF prepared to NiV. RIP assays were performed as described in
Section 2.
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Fig. 3. Analysis of serum samples from NiV-infected humans by RIP and pseudotype neutralization assay. Panel A shows immunoprecipitation of radio labeled NiV-F and
-G (expressed from recombinant vaccinia virus) with human serum samples collected during outbreaks of NiV. Samples H737, H713, H700, H699 and H677 were from NiV-
infected individuals; samples H675, H661, H658, H680 and H622 were from uninfected contacts. The controls include a serum sample from a volunteer in the laboratory
(Neg), a positive control human serum sample from the initial outbreak of NiV inMalaysia (Hum+), and HMAF to NiV. Panel B shows the ability of the serum samples to inhibit
luciferase activity in Vero cells infected with pVSV-NiV-F/G. Serum samples were tested at fourfold dilutions beginning at 1:40 and the infections and luciferase assays were
performed as described in Section 2. Negative controls samples are indicated by dashed lines and NiV positive samples have solid lines.
NiV-G and -F (Fig. 3A). These results conﬁrmed that the serum sam-
ples to be evaluated in the neutralization assay included antibodies
speciﬁc to the surface glycoproteins of NiV.
3.3. Comparison of the pVSV-NiV-F/G assay and PRNT
The human serum samples containing antibodies to NiV-F and
-G completely inhibited the luciferase production in Vero cells
infected with pVSV-NiV-F/G at dilutions of up to1:640 (Fig. 3B).
Control serum samples did not inhibit luciferase production at the
starting dilution of 1:40. These data showed that the human serum
samples were able to neutralize the infectivity of the pseudotype
particles.
All of the serum samples from the pigs vaccinated with CP-F,
CP-G or CP-F and CP-G were tested in both the standard PRNT and
Fig. 4. Comparison of the results of PRNTwith the neutralization assays using pVSV-
NiV-F/G as antigen. Graphs show geometric mean titers (GMT) from both assays
(pVSV-NiV-F/G in top graph; PRNT in lower graph) for serum collected 0, 7, 14, 21,
28, 35, 42 and 49dpv (pigs receiving high dose vaccine only are shown).
the assay using pVSV-NiV-F/G as an antigen (Fig. 4). Both assays
consistently detected neutralizing antibodies to NiV in the serum
samples obtained after the booster vaccination on day 21, and the
assays based on the pVSV-NiV-F/G demonstrated high sensitivity
and speciﬁcity compared to standard PRNT (Fig. 5). However, the
sensitivity of the pVSV-NiV-F/G assay was decreased to approxi-
mately 50% with serum samples collected 7, 14 and 21dpv. PRNT
detected low levels of antibodies more efﬁciently than the pseudo-
type assay or RIP. Overall, the speciﬁcity of the pseudotype assay
was extremely high (94–100%) and none of the pre-vaccination
serum samples were positive in either assay (Figs. 4 and 5). When
samples were scored as positive or negative, there was a 96% cor-
relation between the results of the pseudotype assay and PRNT
with only 16 discordant results for 363 serum samples, 15 of which
occurred for samples taken 7–21dpv (Fig. 5). Therewas nearly 100%
correlation for all of the pre-bleed samples and for samples taken
28–49dpv. Comparing the titers for the PRNT andpseudotype assay
gave a coefﬁcient of correlation of 0.51 for all samples collected
on days 28–49. Serum samples from the pigs receiving the high
dose of the vaccines had an overall correlation coefﬁcient of 0.62
and 0.68 for the samples from days 28 and 35 post-vaccination,
respectively.
4. Discussion
Several strategies have been employed to develop new diag-
nostic techniques to detect infections with the henipaviruses with
an emphasis on assays that do not require BSL-4 containment.
Expression systems were used to produce antigens for enzyme
immunoassays including theNiV-N protein (Chen et al., 2006; Yu et
al., 2006), a truncated phosphoprotein antigen (Chen et al., 2007),
or the glycoproteins of NiV (Eshaghi et al., 2005a,b, 2004). Other
assays described the use of monoclonal antibodies for immuno-
histochemical based diagnosis (Tanimura et al., 2004; Xiao et al.,
2008), or a modiﬁed plaque assay in which the plates are prepared
in BSL-4 and inactivated by gamma irradiation before staining at
BSL-2 (Crameri et al., 2002). Soluble G proteins coupled with a bio-
plex protein array have been used to measure antibody responses
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Fig. 5. Sensitivity and speciﬁcity of the pseudotype neutralization assays compared to PRNT. Figure shows comparison tables of the results from the neutralization assay
using VSV-NiV-F/G and PRNT. Serum samples were collected at 0, 7, 14, 21, 28, 35, 42 and 49dpv. All animals were boosted on day 21. Results from pigs receiving high dose
and low dose vaccinations are included.
to the glycoproteins of henipaviruses and the results showed a good
correlation to PRNT (Bossart et al., 2007).
The pVSV-NiV-F/G was initially developed to support studies
to identify the cellular receptors for the henipaviruses and has
recently been used as antigen for a neutralization test (Wang
et al., 2006). A similar approach using pseudotype particles or
reporter virus particles (RVP) was used in a neutralization assay
for SARS (Temperton et al., 2005) and West Nile virus (Pierson et
al., 2006). This report describes the ﬁrst comparison between the
neutralization assay using pVSV-NiV-F/G and PRNT. The VSV-NiV-
F/G neutralization assay offers several signiﬁcant advantages over
PRNT. The assay can be performed entirely at BSL-2, completed
in less than 48h, and relies on automated read-outs in a 96-well
format instead of manual counting of plaques. Overall, the results
obtained by the assay using pVSV-NiV-F/G were consistent and
correlated well with the results from PRNT. Both methods (Fig. 4)
conﬁrmed previous reports of the ability of NiV-G to induce higher
neutralizing titers than NiV-F (Bossart et al., 2005; Guillaume et al.,
2006; Mungall et al., 2006; Tamin et al., 2002). Also, the pseudo-
type particles were immunogenic when used as an antigen in an
indirect enzyme immunoassay format suggesting that this may be
a promising technique for developing glycoprotein speciﬁc enzyme
immunoassays for NiV and other paramyxoviruses.
There is considerable variation in all diagnosticmethods, includ-
ing PRNT, in detecting low levels of antibodies. In this study, the
results of the PRNT were regarded as the gold standard. Fifteen of
the 16 discordant results between PRNT and the pseudotype neu-
tralization assay were recorded from serum samples collected 7,
14 and 21dpv when antibody levels were very low. With only one
exception, the PRNT titers did not exceed 40 for any of the sam-
ples that appeared to give false negative results in the pseudotype
assay. Some of these low titers could have been due to toxic effects
of the serum in the PRNT assay. All of the ﬁve apparent false posi-
tive results in the pseudotype assay were from the serum samples
collected on day 21 and these had the titers of 40.
Henipaviruses are zoonotic viruses, and their natural reservoir
is fruit bats of the genus Pteropus (Halpin et al., 2000; Chua et al.,
2002). The geographical distribution of Pteropus fruit bats includes
parts of West Africa, South Asia and Southeast Asia, the Paciﬁc
Islands, and the eastern coast of Australia. This vast area includes
some of the most heavily populated areas in the world includ-
ing many developing countries (Epstein et al., 2006). Unlike other
paramyxoviruses, these viruses have the ability to infect a wide
range of host species (Bellini et al., 2005). Therefore, there is always
the potential for spillover of henipaviruses from the natural reser-
voir into humans or farm animals. Good laboratory tests, including
both serologic and virus detection methods are needed to rapidly
detect outbreaks of henipaviruses.
The standard ﬁrst-line serologic test for henipaviruses has been
enzyme immunoassay along with neutralization tests used for
conﬁrmation. The pseudotype neutralization assay described here
could be used to replace PRNT as the conﬁrmatory serologic test
in areas lacking high containment facilities. Pseudotype parti-
cles could easily be prepared in advance and stored frozen until
required. The local laboratorywould need only cell culture capacity
and a luminometer. This new novel, high-throughput assay could
also be a valuable tool for performing serologic surveillance of var-
ious bat species and domestic animals. Finally, this assay would
provide a convenient and safeway tomeasure protective antibodies
induced by experimental vaccines against henipaviruses.
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